Computational Biology Market Size Worth $13.6 Billion by 2026
Antifreeze Proteins Market Will Register a CAGR of Over 30 Percent by 2023
Impending Patent Cliff Threatens Billions of Global Prescription Drug Sales
Over $198 billion in global prescription drug sales are at risk between 2019-2024 from patent expirations, according to a new report from EvaluatePharma. Experts are now warning that the pharmaceutical industry is on the brink of a second patent cliff. Worldwide prescription drug sales are expected to grow at a CAGR of 6.9 percent to $842…
FDA Approves First Treatment for Episodic Cluster Headache
The U.S. Food and Drug Administration approved Emgality (galcanezumab-gnlm) solution for injection for the treatment of episodic cluster headache in adults. “Emgality provides patients with the first FDA-approved drug that reduces the frequency of attacks of episodic cluster headache, an extremely painful and often debilitating condition,” said Eric Bastings, M.D., deputy director of the Division…
FDA Approves New Treatment for Hospital-acquired, Ventilator Associated Bacterial Pneumonia
The U.S. Food and Drug Administration approved a new indication for the previously FDA-approved drug, Zerbaxa (ceftolozane and tazobactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older. The FDA initially approved Zerbaxa in 2014 to treat complicated intra-abdominal infections and for complicated urinary tract infections.…
Global Pulmonary Arterial Hypertension Market Size Expected to Reach $9.3 Billion by 2026
The global pulmonary arterial hypertension market size is expected to reach USD 9.3 billion by 2026. It is projected to progress at a CAGR of 5.6 percent during the forecast period. Increasing prevalence of Pulmonary Arterial Hypertension (PAH) and government support for the development of orphan drugs are fueling the growth. The cases of PAH…
North America Projected to Generate $635 Billion in Pharmaceutical Sales by 2022
North America is expected to continue to lead global pharmaceutical sales in the year 2022, with $635 billion expected that year, according to a March 2019 report from biopharmaceutical company AstraZeneca. The United States, China, Japan, Germany and France led the world pharmaceutical sales market in 2018, with the United States having 47.2 percent of…
FDA Approves Innovative Gene Therapy to Treat Pediatric Patients with Spinal Muscular Atrophy
The U.S. Food and Drug Administration today approved Zolgensma (onasemnogene abeparvovec-xioi), the first gene therapy approved to treat children less than two years of age with spinal muscular atrophy (SMA), the most severe form of SMA and a leading genetic cause of infant mortality. “Today’s approval marks another milestone in the transformational power of gene…
Progressive Supranuclear Palsy Therapeutics Market Will Register a CAGR of 5 Percent by 2023
The increasing strategic alliances are expected to trigger the progressive supranuclear palsy therapeutics market growth during the forecast period. Vendors in the market are entering into strategic alliances for co-developing and co-commercializing drugs of for licensing the drugs to large pharmaceutical vendors including the academic institutions and several small pharmaceutical vendors lacking the advanced manufacturing…